Financial Statements March 31, 2021

#### Financial Statements March 31, 2021

#### **Table of Contents**

| Independent Auditor's Report           | 1 - 2  |
|--|--------|
| Statement of Financial Position        | 3      |
| Statement of Changes in Fund Balances  | 4      |
| Statement of Revenues and Expenditures | 5 - 6  |
| Statement of Cash Flows                | 7      |
| Notes to Financial Statements          | 8 - 15 |

### RICHTER

#### **Independent Auditor's Report**

To the Directors of Sir Mortimer B. Davis Jewish General Hospital Foundation

#### Opinion

We have audited the financial statements of Sir Mortimer B. Davis Jewish General Hospital Foundation (the Foundation), which comprise the statement of financial position as at March 31, 2021, and the statements of revenues and expenditures, changes in fund balances and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Foundation as at March 31, 2021, and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

#### Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Foundation in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Montréal, Québec September 9, 2021

## Statement of Financial Position As at March 31, 2021

| ·   | General<br>Fund<br>\$ | Endowment<br>Fund<br>\$ | Externally<br>Restricted<br>Fund<br>\$ | Total<br>2021<br>\$ | Total<br>2020<br>\$ |
|---|-----------------------|-------------------------|--|---------------------|---------------------|
| Assets                                      |                       |                         |  |                     |                     |
|   | 27 540 727            |                         |  | 27 542 727          | 20,000,000          |
| Cash Marketable securities, at quoted       | 37,542,727            | -                       | -                                      | 37,542,727          | 36,000,902          |
| values (note 3)                             | 235,049,251           | -                       | -                                      | 235,049,251         | 202,816,356         |
| Interest and sundry receivables             | 752,049               |                         |  | 752,049             | 1,044,778           |
| Interfund loans (note 4)                    | (198,975,097)         | 139,625,617             | 59,349,480                             | 732,049             | 1,044,776           |
| Pledges receivable                          | 4,950,054             | -                       | 66,345,234                             | 71,295,288          | 64,973,761          |
| Property and equipment (note 5)             | 1,543,329             | -                       | -                                      | 1,543,329           | 1,545,192           |
|   | 80,862,313            | 139,625,617             | 125,694,714                            | 346,182,644         | 306,380,989         |
|   |                       |                         |  |                     |                     |
| Liabilities                                 |                       |                         |  |                     |                     |
| Accounts payable and                        |                       |                         |  |                     |                     |
| accrued liabilities                         | 251,870               | -                       | -                                      | 251,870             | 926,004             |
| Due to hospital (note 4)                    | 6,339,552             | -                       | -                                      | 6,339,552           | 5,531,854           |
| Deferred pledges and contributions (note 7) | 23,348,834            | _                       | 54,988,044                             | 78,336,878          | 72,392,943          |
| Promissory note to Hospital (note 8)        | 3,315,089             | -                       | -                                      | 3,315,089           | 3,867,604           |
|   | 33,255,345            | =                       | 54,988,044                             | 88,243,389          | 82,718,405          |
| Commitments and contingencies (not          | e 9)                  |                         |  |                     |                     |
| Fund balances                               |                       |                         |  |                     |                     |
| Internally restricted (note 10)             | 47,606,968            | -                       | -                                      | 47,606,968          | 38,713,205          |
| Externally restricted                       | -                     | -                       | 70,706,670                             | 70,706,670          | 66,293,960          |
| Endowments                                  | -                     | 139,625,617             | -                                      | 139,625,617         | 118,655,419         |
|   | 47,606,968            | 139,625,617             | 70,706,670                             | 257,939,255         | 223,662,584         |
|   | 80,862,313            | 139,625,617             | 125,694,714                            | 346,182,644         | 306,380,989         |

| Approved by, |      |  |
|--------------|------|--|
|              | Date |  |
|              | Date |  |

## Statement of Changes in Fund Balances For the Year Ended March 31, 2021

|  | General Fund                   | Endowment<br>Fund | Externally<br>Restricted<br>Fund | _                   |
|--|--------------------------------|-------------------|----------------------------------|---------------------|
|  | Internally<br>restricted<br>\$ | Endowment<br>\$   | Restricted<br>\$                 | Total<br>2021<br>\$ |
| Balance - beginning of year                            | 38,713,205                     | 118,655,419       | 66,293,960                       | 223,662,584         |
| Excess of revenues over expenses                       | 6,252,386                      | 20,974,009        | 7,050,276                        | 34,276,671          |
| Interfund transfers                                    | 2,641,377                      | (3,811)           | (2,637,566)                      | -                   |
| Balance - end of year                                  | 47,606,968                     | 139,625,617       | 70,706,670                       | 257,939,255         |
|  | General Fund                   | Endowment Fund    | Externally<br>Restricted<br>Fund | _                   |
|  | Internally<br>restricted<br>\$ | Endowment<br>\$   | Restricted<br>\$                 | Total<br>2020<br>\$ |
| Balance - beginning of year                            | 39,963,893                     | 122,712,592       | 62,691,403                       | 225,367,888         |
| Excess of revenues (expenses) over expenses (revenues) | 306,010                        | (4,058,269)       | 2,046,955                        | (1,705,304)         |
| Interfund transfers                                    | (1,556,698)                    | 1,096             | 1,555,602                        | -                   |
| Balance - end of year                                  | 38,713,205                     | 118,655,419       | 66,293,960                       | 223,662,584         |

# Statement of Revenues and Expenditures For the Year Ended March 31, 2021

|   | General<br>Fund<br>\$                            | Endowment<br>Fund<br>\$ | Externally<br>Restricted<br>Fund<br>\$ | Total<br>2021<br>\$                               | Total<br>2020<br>\$                               |
|---|--|-------------------------|--|---|---|
| Revenues  |  |                         |  |   |   |
| Donations and fundraising (note 11)   |  |                         |  |   |   |
| Annual campaign and other donations Designated for hospital Fundraising events Surcharge fee  | 3,318,320<br>1,587,321<br>3,793,468<br>5,578,995 | 776,319<br>-<br>-<br>-  | 24,285,315<br>-<br>-<br>-              | 28,379,954<br>1,587,321<br>3,793,468<br>5,578,995 | 22,763,187<br>1,329,705<br>9,669,133<br>4,473,975 |
| N   | 14,278,104                                       | 776,319                 | 24,285,315                             | 39,339,738  | 38,236,000  |
| Net transfers to<br>deferred contributions<br>from fundraising events (note 7)<br>Net transfers to deferred<br>contributions from capital | (1,151,801)                                      | -                       | -                                      | (1,151,801)                                       | (1,485,350)                                       |
| campaign  | -  | -                       | (99,023)                               | (99,023)  | (1,130,822)                                       |
| Total revenues from donations and fundraising   | 13,126,303                                       | 776,319                 | 24,186,292                             | 38,088,914  | 35,619,828  |
|   | 13,126,303                                       | 776,319                 | 24,186,292                             | 38,088,914  | 35,619,828  |
| Expenses  |  |                         |  |   |   |
| Fundraising events<br>Campaign and sundry<br>Foundation administrative  | 2,226,147<br>2,663,525                           | -                       | -                                      | 2,226,147<br>2,663,525                            | 4,100,609<br>1,911,247                            |
| expenses Investment management fees   | 3,896,506<br>85,620                              | -<br>323,018            | -<br>-                                 | 3,896,506<br>408,638                              | 3,360,137<br>244,095                              |
| Amortization  | 96,863<br>8,968,661                              | 323.018                 | <del>-</del>                           | 96,863<br>9,291,679                               | 96,863<br>9,712,951                               |
| Excess of revenues over expenses before investment returns  |  | ,-                      |  |   |   |
| and allocations   | 4,157,642  | 453,301                 | 24,186,292                             | 28,797,235  | 25,906,877  |
| Investment returns  Dividend, interest and qains on sale of   |  |                         |  |   |   |
| marketable securities Change in fair value of   | 3,701,367  | 5,374,698               | -                                      | 9,076,065   | 7,311,013   |
| marketable securities   | 5,373,806  | 18,143,745              | -                                      | 23,517,551  | (10,279,231)                                      |
|   | 9,075,173  | 23,518,443              | -                                      | 32,593,616  | (2,968,218)                                       |
| Excess of revenues over expenses before allocations   | 13,232,815                                       | 23,971,744              | 24,186,292                             | 61,390,851  | 22,938,659  |

# **Statement of Revenues and Expenditures For the Year Ended March 31, 2021**

|   |                       |                         | Externally               |                     |                     |
|---|-----------------------|-------------------------|--------------------------|---------------------|---------------------|
|   | General<br>Fund<br>\$ | Endowment<br>Fund<br>\$ | Restricted<br>Fund<br>\$ | Total<br>2021<br>\$ | Total<br>2020<br>\$ |
| Allocations to the Sir Mortimer B. Davis Jewish General Hospital and other establishments |                       |                         |                          |                     |                     |
| Research and academic   |                       |                         |                          |                     |                     |
| enhancement<br>Capital projects and   | 3,437,475             | -                       | -                        | 3,437,475           | 1,757,854           |
| equipment   | 439.984               | _                       | 7,470,939                | 7,910,923           | 6,053,960           |
| Designated for hospital   | 2,244,786             | 42,247                  | 8,078,590                | 10,365,623          | 9,205,203           |
| Endowment allocations   | -                     | 2,657,663               | -                        | 2,657,663           | 2,038,152           |
| Allocations to other  |                       |                         |                          |                     |                     |
| establishments  | 146,650               | 297,825                 | -                        | 444,475             | 819,597             |
| Allocation to hospital for  |                       |                         |                          |                     |                     |
| building projects   | 711,534               | -                       | 1,586,487                | 2,298,021           | 4,769,197           |
|   | 6,980,429             | 2,997,735               | 17,136,016               | 27,114,180          | 24,643,963          |
| Excess of (expenses) revenues over (revenues) expenses                                    |                       |                         |                          |                     |                     |
| and allocations   | 6,252,386             | 20,974,009              | 7,050,276                | 34,276,671          | (1,705,304)         |

#### Statement of Cash Flows For the Year Ended March 31, 2021

|  | 2021<br>\$                             | 2020<br>\$                            |
|--|--|---------------------------------------|
| Operating activities   |  |                                       |
| Excess of (expenses) revenues over (revenues) expenses and allocations   | 34,276,671                             | (1,705,304)                           |
| Amortization Increase (decrease) in fair value of marketable securities Decrease (increase) in -                       | 96,863<br>(23,517,551)                 | 96,863<br>10,279,230                  |
| Interest and sundry receivables Pledges receivable Due to hospital Increase (decrease) in -                            | 292,729<br>(6,321,527)<br>807,698      | (589,508)<br>(5,527,076)<br>2,011,136 |
| Accounts payable and accrued liabilities  Deferred pledges and contributions   | (674,134)<br>5,943,935                 | 35,688<br>7,510,041                   |
|  | 10,904,684                             | 12,111,070                            |
| Investing activities   |  |                                       |
| Proceeds on disposition of marketable securities Purchase of marketable securities Additions to property and equipment | 25,841,329<br>(34,556,673)<br>(95,000) | 72,289,112<br>(79,140,175)            |
|  | (8,810,344)                            | (6,851,063)                           |
| Financing activity   |  |                                       |
| Promissory note to Hospital  | (552,515)                              | (552,515)                             |
| Increase in cash   | 1,541,825                              | 4,707,492                             |
| Cash - beginning of year   | 36,000,902                             | 31,293,410                            |
| Cash - end of year   | 37,542,727                             | 36,000,902                            |

## Notes to Financial Statements March 31, 2021

#### 1. Purpose of the Foundation

The principal activity of the Foundation is to raise funds for research in the field of medicine and for the development of related health care activities for the Sir Mortimer B. Davis Jewish General Hospital. The Foundation is incorporated under the Canada Corporations Act as a not-for-profit organization and is a registered charity under the Income Tax Act.

#### 2. Summary of significant accounting policies

The Foundation has elected to apply Canadian accounting standards for not-for-profit organizations (ASNFPO) in Part III of the CPA Canada Handbook - Accounting.

The Foundation also applies Canadian standards for private enterprises to the extent that these standards address topics not addressed in Canadian accounting standards for not-for-profit organizations.

#### **Fund accounting**

The General Fund reports on revenues and expenses related to annual donations and fundraising activities which subsidizes research, teaching, medical technology and related expenditures.

Endowment contributions are reported in the Endowment Fund. Investment income earned on resources of the Endowment Fund is reported in the Endowment Fund or the General Fund depending on the nature of any restrictions imposed by contributors of these funds.

The Externally Restricted Fund reports on contributions which generally are pledged and subsequently paid over a fixed period of time. Such contributions are being raised to enhance the capital of the Foundation or for specific projects of the Hospital.

#### Revenue recognition

The Foundation follows the restricted fund method of accounting for contributions.

Unrestricted contributions are recognized as revenue of the appropriate fund when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Contributions for endowment are recognized as revenue, when received, in the Endowment Fund.

Externally restricted contributions are recorded when received or pledged. Such contributions are deferred and recognized as revenue in the year in which the related expenses are incurred.

Surcharge fees comprise an administration charge used to i.) fund the infrastructure costs of the Lady Davis Institute and the Foundation; and ii.) fund innovation at the Lady Davis Institute and the Jewish General Hospital and are recognized on all gifts and donations when received in the year.

## Notes to Financial Statements March 31, 2021

#### 2. Summary of significant accounting policies (continued)

#### Revenue recognition (continued)

Investment transactions are accounted for on the transaction date. Gains or losses on the disposal of investment are determined using the average cost method. Interest income is recognized on the accrual basis as earned.

#### Use of estimates

The preparation of financial statements in conformity with Canadian accounting standards for not-for-profit organizations requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

#### Property and equipment

Property and equipment are accounted for at cost. Amortization for the buildings is calculated on their respective estimated useful life using the straight-line method over a period of 20 years.

#### Long-lived asset

The Foundation tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Recoverability is assessed by comparing the carrying amount to the estimated undiscounted future net cash flows the long-lived assets are expected to generate, through their direct use and eventual disposition. When a test for impairment indicates that the carrying amount of an asset is not recoverable, an impairment loss is recognized to the extent carrying value exceeds its fair value.

#### Foreign currency translation

Accounts in foreign currency have been translated into Canadian dollars as follows:

- Monetary items at exchange rates in effect at the balance sheet date;
- Non-monetary items at exchange rates in effect on the dates of the transactions; and
- Revenue and expenses at average exchange rates prevailing during the year.

Gains and losses arising from foreign currency translation are included in the statement of revenues and expenditures.

Notes to Financial Statements March 31, 2021

#### 2. Summary of significant accounting policies (continued)

#### **Financial instruments**

The Foundation initially measures its financial assets and financial liabilities at fair value, except for certain non-arm's length transactions. The Foundation subsequently measures its financial assets and financial liabilities at amortized cost, except for investments in equity instruments that are quoted in an active market and derivative financial instruments that do not qualify as a hedge, which are measured at fair value with changes in fair value recognized in the statement of revenues and expenditures.

Financial assets subsequently measured at amortized cost are tested for impairment when there are indicators of possible impairment. Any impairment loss is recognized in the statement of revenues and expenditures. The previously recognized impairment loss may subsequently be reversed to a maximum of the amortized cost that would have been reported at the date of the reversal had the impairment not been recognized previously.

The carrying amount of financial instruments that are subsequently measured at amortized cost is adjusted by the transaction costs, which are recognized in the statement of revenues and expenditures using the straight-line method. Transaction costs related to financial instruments that are subsequently measured at fair value are recognized in the statement of revenues and expenditures in the period incurred.

#### 3. Marketable securities

|                                  | 2021<br>\$                | 2020<br>\$                |
|----------------------------------|---------------------------|---------------------------|
| Equities Fixed income securities | 173,576,235<br>61,473,016 | 147,894,097<br>54,922,259 |
|                                  | 235,049,251               | 202,816,356               |

Marketable securities are carried in the accounts at their quoted values and any change in fair value is recorded in the statement of revenues and expenditures.

Included in marketable securities is the fair value of the derivative financial instruments (note 9).

#### 4. Interfund loans and due to Hospital

Interfund loans and amounts due to Hospital are non-interest bearing and have no specific terms of repayment.

Notes to Financial Statements March 31, 2021

#### 5. Property and equipment

|                   | Cost<br>\$          | Accumulated amortization | 2021<br>Net carrying<br>amount<br>\$ | 2020<br>Net carrying<br>amount<br>\$ |
|-------------------|---------------------|--------------------------|--------------------------------------|--------------------------------------|
| Land<br>Buildings | 56,400<br>2,835,560 | -<br>1,348,631           | 56,400<br>1,486,929                  | 56,400<br>1,488,792                  |
|                   | 2,891,960           | 1,348,631                | 1,543,329                            | 1,545,192                            |

#### 6. Credit facility

The Foundation's credit facility provides for a \$5,000,000 line of credit with borrowings thereunder bearing interest at bank prime rate per annum. As at March 31, 2021, there was no bank indebtedness outstanding (2020 - \$Nil).

#### 7. Deferred pledges and contributions

|  | Deferred<br>pledges<br>\$ | Deferred<br>contributions<br>\$ | 2021<br>Total<br>\$ | 2020<br>Total<br>\$ |
|--|---------------------------|---------------------------------|---------------------|---------------------|
| Balance - beginning of year                                | 55,356,822                | 17,036,121                      | 72,392,943          | 64,882,902          |
| Recognized this year<br>Amounts received or receivable for | (27,656,575)              | (1,859,972)                     | (29,516,547)        | (21,491,904)        |
| future periods   | 32,237,854                | 3,222,628                       | 35,460,482          | 29,001,945          |
| Balance - end of year                                      | 59,938,101                | 18,398,777                      | 78,336,878          | 72,392,943          |

The net transfers from deferred contributions to fundraising events consists of the following:

|  | 2021<br>\$  | 2020<br>\$  |
|--|-------------|-------------|
| Transfers from deferred contributions to fundraising events relating to expenditures incurred in the year Transfers to deferred contributions from fundraising | 1,859,972   | 3,720,160   |
| events in the current year   | (3,011,773) | (5,205,510) |
|  | (1,151,801) | (1,485,350) |

#### 8. Promissory note - Sir Mortimer B. Davis Jewish General Hospital

The promissory note is non-interest bearing and repayable in 10 equal annual instalments of approximately \$550,000 that started in fiscal year 2017.

Notes to Financial Statements March 31, 2021

#### 9. Commitments and contingencies

#### Investment purchase commitments

In its long-term investment pool, the Foundation has entered into agreements to purchase various equity investments for a total commitment of approximately \$142,900,000 of which approximately \$93,400,000 has been purchased as at March 31, 2021.

#### Pavilion K project of Sir Mortimer B. Davis Jewish General Hospital

The Foundation has guaranteed the debt service with respect to the loan which funds the construction costs of the parking structure related to the Hospital's Pavilion K project. The balance of the debt related to the parking structure amounted to approximately \$17.81 million as at March 31, 2021 and is bearing 4.31% interest on an annual basis. The loan is repayable over 25 years and matures in 2038, and it is intended that the debt service of the loan and operating costs of the parking structure will be funded from the parking revenue. Should such revenue not be sufficient, the Foundation will be liable, on an annual basis, to fund the shortfall. To date, there has been no annual shortfall and no funding has been provided by the Foundation in this regard, nor have any future needs been identified.

#### Sir Mortimer B. Davis Jewish General Hospital

The Foundation has made a commitment to provide approximately \$3,100,000, in fiscal 2022, of funding to the Sir Mortimer B. Davis Jewish General Hospital to be applied towards supplementary activities ("activités accessoires").

#### **Rossy Cancer Network**

The Foundation has made a commitment to the Rossy Cancer Network for an amount of \$7,200,000 in 2014 to establish a cancer network and improve the identification of cancer indicators and quality of cancer care.

The remaining committed payments are due approximately as follows:

|            | \$        |
|------------|-----------|
| 2022       | 545,000   |
| 2023       | 545,000   |
| 2024       | 545,000   |
| 2025       | 545,000   |
| 2026       | 545,000   |
| Thereafter | 1,106,978 |
|            | 3,831,978 |

Notes to Financial Statements March 31, 2021

#### 9. Commitments and contingencies (continued)

#### Foreign exchange contracts

As at March 31, 2021, the Foundation has a contractual obligation through forward exchange contracts to sell a fixed amount of U.S.\$22,216,563 for CDN\$28,583,293 maturing on April 5, 2021 and to sell a fixed amount of CDN\$28,371,966 for U.S.\$22,216,563 maturing on April 5, 2021. As explained in note 2, the Foundation accounts for these financial instruments as non-hedging derivative financial instruments. The Foundation's derivatives dealer established the forward exchange contracts' fair value at a gain of approximately \$211,000.

#### 10. Internally restricted net assets

As at March 31, 2021, the Foundation's board of directors has internally restricted capital of \$47,606,968, in aggregate, which consists of \$46,063,639 of the General Fund which consists of estates, bequests and other capital amounts and the remaining internally restricted capital of the General Fund Capital of \$1,543,329 relates to property and equipment.

#### 11. Donations

Donations recorded during the years ended March 31, 2021 and 2020 were from the following categories of donors:

|  | 2021<br>\$ | 2020<br>\$ |
|--|------------|------------|
| Foundations and not-for-profit organizations | 6,187,514  | 6,661,355  |
| Individuals                                  | 26,107,640 | 19,771,732 |
| Corporations                                 | 7,044,584  | 11,802,913 |
|  | 39,339,738 | 38,236,000 |

Notes to Financial Statements March 31, 2021

#### 12. Financial instruments

The Foundation is exposed to various risks through its financial instruments. The following analysis provides a measure of the risks at the financial position date.

#### **Currency risk**

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

Some assets are exposed to foreign exchange fluctuations. As at March 31, 2021, assets in foreign exchange are the following:

|   | 2021                            |                                 | 2020                             |                                  |
|---|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
|   | Canadian<br>dollars<br>\$       | Foreign<br>currency             | Canadian<br>dollars<br>\$        | Foreign<br>currency              |
| Cash (U.S.\$) Marketable securities (U.S.\$) Marketable securities (Euro) | 71,000<br>88,435,000<br>228,000 | 57,000<br>70,326,000<br>155,000 | 710,000<br>74,715,000<br>343,000 | 500,000<br>52,664,000<br>220,000 |

The Foundation's activities involve investments denominated in foreign currencies. These activities result in exposure to fluctuations in foreign currency rates. The Foundation enters into foreign exchange contracts to mitigate the risk.

#### Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

The Foundation is exposed to reductions in interest rates, which could adversely impact expected returns from the Foundation's reinvestment of funds in marketable securities upon maturity of such instruments.

#### Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

The Foundation is exposed to credit risk only with respect to uncertainty as to timing and amount of collectibility of sundry receivables and pledges receivable. Historically, the Foundation collects virtually all of its pledges receivable.

Notes to Financial Statements March 31, 2021

#### 12. Financial instruments (continued)

#### Market risk

Market risk, which includes other price risk, is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The Foundation's investments in publicly traded securities expose the Foundation to market risk as such investments are subject to price changes in the open market. The Foundation mitigates the risk by regularly rebalancing its portfolio to ensure proper diversification.

#### Price risk

The Foundation is exposed to securities price risk because of investments held by the Foundation. To manage its price risk arising from investments in securities, the Foundation diversifies its portfolio. Diversification of the portfolio is done in accordance with the limits set by the Foundation.

#### Liquidity risk

Liquidity risk is the risk that the Foundation will have difficulty in meeting obligations associated with financial liabilities. Prudent management of liquidity risk implies retaining a sufficient level of liquidity and arranging for appropriate credit facilities and being able to liquidate market positions. The Foundation believes that its recurring financial resources are adequate to cover all its expenditures.

#### 13. Impact of COVID-19

On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus ("COVID-19") as a global pandemic, which continues to spread throughout Canada and around the world.

As of the report date, the Foundation is aware of changes in its operations as a result of COVID-19, notably the cancellation or re-organizing of certain events. The Foundation did not apply for government subsidy programs and is continuing with operations as normal.

Management is uncertain of the impacts of those changes on its financial statements and believes any disruption, when and if experienced, could be temporary; however, there is uncertainty around when any disruption might occur, the duration and hence the potential impact. As a result, we are unable to estimate the potential impact on our operations as of the date of this report.